MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma

Costa, Pedro M.; Cardoso, Ana L.; Custódia, Carlos; Cunha, Pedro P.; Almeida, Luís Pereira de; Lima, Maria C. Pedroso de

doi:10.1016/j.jconrel.2015.04.002

Cited by 177 publications

(133 citation statements)

References 37 publications

Supporting

Mentioning

130

Contrasting

Unclassified

Order By: Relevance

“…The formulation of nano vehicles for RNAi is critical for the clinical success. Early efforts focused on dendrimer inspired nano constructs and solid nanoparticles (NPs), followed by the biomimetic development of tumor derived exosome-based experimental therapeutics for brain delivery [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19]. The engineering potential of cell type selectivity for these vehicles is limited.…”

Section: Evolving Nano Formulations Of Rnai Expand Therapeutic Potentmentioning

confidence: 99%

“…Multi-targeting capacity is vital for nanoRNAi formulations against patient specific GBM The evolution of nano carriers for siRNAs started with single core solid nano constructs based on classic materials such as gold [24], iron oxide, chitosan [5,17], porous silica [8], sugar [15], solid lipids [3,4,6,9] and an array of dendrimer inspired NPs [12]. Some of these applications showed early promise in effective RNAi of key GBM growth-promoting genes: Jensen et al demonstrated that gold NP mediated siRNA knockdown of the oncoprotein Bcl2Like12 (Bcl2L12) reduced tumor growth [24]; Costa et al demonstrated effective GBM inhibition using anti-miR-21 oligonucleotides, a different approach for tumor promoting miR-21 silencing [4];…”

Section: Evolving Nano Formulations Of Rnai Expand Therapeutic Potentmentioning

confidence: 99%

“…Some of these applications showed early promise in effective RNAi of key GBM growth-promoting genes: Jensen et al demonstrated that gold NP mediated siRNA knockdown of the oncoprotein Bcl2Like12 (Bcl2L12) reduced tumor growth [24]; Costa et al demonstrated effective GBM inhibition using anti-miR-21 oligonucleotides, a different approach for tumor promoting miR-21 silencing [4];…”

Section: Evolving Nano Formulations Of Rnai Expand Therapeutic Potentmentioning

confidence: 99%

See 2 more Smart Citations

Multiplexed Nanomedicine for Brain Tumors: Nanosized Hercules to Tame Our Lernaean Hydra inside?

Panek

Khan

et al. 2017

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Section: Evolving Nano Formulations Of Rnai Expand Therapeutic Potentmentioning

confidence: 99%

Section: Evolving Nano Formulations Of Rnai Expand Therapeutic Potentmentioning

confidence: 99%

Section: Evolving Nano Formulations Of Rnai Expand Therapeutic Potentmentioning

confidence: 99%

See 1 more Smart Citation

Multiplexed Nanomedicine for Brain Tumors: Nanosized Hercules to Tame Our Lernaean Hydra inside?

Panek

Khan

et al. 2017

Nanomedicine (Lond.)

View full text Add to dashboard Cite

“…To analyze the in vitro cellular uptake, HepG2 cells were seeded into the 12-well plates at a density of 1.5×10 5 per well and incubated overnight at 37°C. Then the culture medium was replaced by fresh RPMI 1640 containing free Cy3-labled siRNA or different liposomal formulation.…”

Section: In Vitro Cytotoxicitymentioning

confidence: 99%

“…[5][6][7] In recent studies, the most prevalent method to achieve the synergistic effort of drug and siRNA is incorporating anticancer drug and siRNA into one nanocarrier that allows effective co-delivery to tumor site. For example, PEGylated liposomes were designed to co-encapsulate antibcr-abl siRNA and imatinib mesylate for chronic myeloid leukemia treatment.…”

mentioning

confidence: 99%

pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery

Yao

Liang

et al. 2015

IJN

View full text Add to dashboard Cite

Combination of chemotherapeutic drug and small interfering RNA (siRNA) can affect multiple disease pathways and has been proven effective in suppressing tumor progression. Co-delivery of drug and siRNA within a same nanocarrier is a vital means in this field. The present study aimed at the development of a pH-sensitive liposome to co-deliver drug and siRNA to tumor region. Driven by the electrostatic interaction, the pH-sensitive material, carboxymethyl chitosan (CMCS), was coated onto the surface of the cationic liposome (CL) preloaded with sorafenib (Sf) and siRNA (Si). To evaluate whether the resulting CMCS-modified Sf and siRNA co-delivery cationic liposome (CMCS-SiSf-CL) enhanced antitumor efficiency after systematic administration, in vitro and in vivo experiments were evaluated in HepG2 cells and the H22 cells-bearing Kunming mice model. The experimental results demonstrated that CMCS-SiSf-CL was able to condense siRNA efficiently and protect siRNA from being degraded by serum and RNase. The release rate of Sf from CMCS-modified liposome exhibited pH-sensitive release behavior. Furthermore, in vitro cellular uptake results showed that CMCS-SiSf-CL yielded higher fluorescence intensity at pH 6.5 than at pH 7.4, and that siRNA could be delivered to tumor site by CMCS-SiSf-CL in vivo. The in vivo antitumor efficacy showed that CMCS-Sf-CL inhibits tumor growth effectively when compared with free Sf solution. In current experimental conditions, this liposomal formulation did not show significant toxicity both in vitro and in vivo. Therefore, co-delivering Sf with siRNA by CMCS-SiSf-CL might provide a promising approach for tumor therapy.

show abstract

Clinical and Translational Opportunities of Nanocarriers Containing RNAi for the Management of Triple‐Negative Breast Cancer

Sharma,

Pradhan,

Lee

et al. 2024

Advanced Therapeutics

View full text Add to dashboard Cite

Triple‐negative breast cancer (TNBC) develops from malignant cells within the interior lining of milk ducts or, less frequently, in the stromal tissues and accounts for around 15% of all breast cancers. Breast cancer is highly prevalent with the overall number of cases expected to reach 27.78 million by 2040, according to the World Health Organization (WHO). MiRNAs serve a novel role in management of breast cancer through their ability to indirectly control the translation of coding mRNA and regulate the expression of specific genes which allows it to play a significant role in cancer therapeutics. However, inherent characteristics of miRNA including rapid clearance via renal excretion, degradation by nucleases in plasma, and additional factors limit its clinical application. To reduce these limitations, miRNA can be administered in conjunction small molecules with nanocarriers which then allow it to impart its benefits including inhibition of epithelial‐mesenchymal transitions, and inhibiting tumor angiogenesis. This review highlights the current application of nanocarrier‐based delivery approach of miRNA/siRNA for triple negative breast cancer treatment.This article is protected by copyright. All rights reserved

show abstract

MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma

Cited by 177 publications

References 37 publications

Multiplexed Nanomedicine for Brain Tumors: Nanosized Hercules to Tame Our Lernaean Hydra inside?

Multiplexed Nanomedicine for Brain Tumors: Nanosized Hercules to Tame Our Lernaean Hydra inside?

pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery

Clinical and Translational Opportunities of Nanocarriers Containing RNAi for the Management of Triple‐Negative Breast Cancer

Contact Info

Product

Resources

About